![]() |
|
|
Vol. 26, Issue 7, 617-622, July 1998
Lorex Pharmaceuticals (S.A., S.S., J.M.) and
Boston Research and
Science Consulting (B.R.-S.)
The objective was to evaluate possible pharmacokinetic and
pharmacodynamic interactions for repeated nightly zolpidem dosing with
fluoxetine. Twenty-nine healthy female volunteers (mean age, 25.6 years) received zolpidem (10 mg) and fluoxetine (20 mg) in the
following open design: zolpidem on night 1 followed by 1 washout day, a
daily morning dose of fluoxetine on days 3 through 27, and a morning
dose of fluoxetine plus an evening dose of zolpidem on days 28 through
32. Plasma levels of zolpidem, fluoxetine, and norfluoxetine were
determined at the transitions from one regimen to the next. Morning
psychomotor tests were performed on days 1, 2, 28, 29, and 33. Steady-state plasma concentrations of fluoxetine/norfluoxetine were
reached by day 24 of fluoxetine dosing. No significant differences in
any pharmacokinetic parameters for fluoxetine and norfluoxetine were
observed between day 27 and day 32. There were no significant
differences in AUC, maximal plasma concentration, or time to maximal
concentration parameters for zolpidem plasma concentrations among
nights 1, 28, and 32. There was a statistically significantly increased
t1/2 for zolpidem on night 32, compared with night 28 (3.64 and 3.29 hr, respectively). There were no
significant differences in the next-morning Digit Symbol Substitution
Test performance at any time in the study. Both zolpidem and fluoxetine
were well tolerated alone or during coadministration. These findings
indicate the absence of clinically significant pharmacokinetic or
pharmacodynamic interactions between fluoxetine and zolpidem (five
consecutive doses) when the drugs are coadministered to healthy women.
Therefore, based on these observations, short-term cotherapy with
fluoxetine (20 mg) and zolpidem (10 mg) appears safe.